Does anyone else think that there is something else at play here with the EMEA?
If Bronchiltol has no major safety issues and overall improves lung function by 8% why not approve it? The reason of variances between 6 year olds and adults seems rubbish. If everyone receives some benefit but in different percentages and you have no major safety risk what is the concern?
We have only 1 major approved product to compete with which earns over $400m revenue a year. A bit of a monopoly if ever there was one.
PXS Price at posting:
85.2¢ Sentiment: Hold Disclosure: Held
